A Phase 1 interventional study of MOB015B and MOB015B vehicle in Erythema, sponsored by Moberg Pharma AB. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-17.
Sponsored by Moberg Pharma AB · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 55 studies in Erythema with a site in United States — 8 open to participants now, 10 under way, none of them phase 3. Erythema · United States.
Among the 55 studies in Erythema with a site in United States, this one is the 7th largest by enrollment of the 52 interventional ones that give a count, is one of 7 that started in 2017, is one of 4 in phase 1, and was the 28th registered.
131 studies on the registry are indexed under Erythema; 17 are open to participants now.
Browse Erythema studies →8 of the 55 studies in Erythema with a site in United States are open now. Recruiting first, the newest first:
Medicines Development for Global Health · Sites in United States, Benin, Côte D'Ivoire and 3 more countries
Ages 18+
Good Molecules, LLC · Sites in United States
Ages 18–75 · Healthy volunteers
University of Nevada, Las Vegas · Sites in United States
Ages 18+
Acorn Biolabs Inc. · Sites in United States, Canada
Ages 18+ · Healthy volunteers
Henry Ford Health System · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 9 Erythema studies recruiting now, 7 set no upper age limit and 2 stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
55 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 9 · Phase 3 5 · Phase 4 4
First in 2005; this study’s year is marked. 7 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 250 is above the median of 50 across 114 interventional studies indexed under Erythema.
Median enrollment 52 across the 52 interventional studies, 104 across the 3 observational. Of the 45 that completed or were terminated, 27 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 55 have an industry lead sponsor. The 10 most frequent:
Moberg Pharma AB is the lead sponsor of 14 studies on the registry; none are open to participants now.
Moberg Pharma AB has 2 studies filed under Erythema — fewer than ten, so there is no comparison to draw.
4 of the studies in Erythema with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07172659Medicines Development for Global HealthEfficacy and Safety Study of Dovramilast in People With Leprosy Type 2 Reaction | 2027-01 |
| NCT06477172Acorn Biolabs Inc.Autologous Hair Follicle Derived Secretome as Adjunct to Aesthetic Procedures | 2027-02 |
| NCT07789639Good Molecules, LLCA Clinical Study to Evaluate the Efficacy and SPF of Two Test Materials According to an Adaptation of the Guidelines of the FDA Sunscreen Drug Products for Over-the-Counter Human Use | 2027-02-24 |
| NCT02876107M.D. Anderson Cancer CenterCarboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer | 2027-10-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 55 studies in Erythema with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A Randomized, Controlled Study to Evaluate the Sensitizing Potential of MOB015B in Healthy Subjects Using a Repeat Insult Patch Test Design To evaluate the sensitization potential
MOB015B is a topical solution for the treatment of nail fungus (onychomycosis) containing the active antifungal ingredient terbinafine. Terbinafine is a well-known antifungal agent that has been widely used for decades for both in topical and oral preparations and is regarded as an effective treatment of dermatophyte infections. In a phase II study, MOB015B was found to be efficacious and safe in the topical treatment of distal subungual onychomycosis. This Phase 1 study will assess the sensitization potential of MOB015B.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patches were applied to the infrascapular area
Drug: MOB015B
Patches were applied to the infrascapular area
Drug: MOB015B vehicle
Patches were applied to the infrascapular area
Drug: Negative irritant solution of 0.9% saline
Topcal formulation
Topcal formulation
Negative control
To determine the potential of MOB015B to induce sensitization by repeated topical application to the healthy skin of humans under controlled conditions.
Evaluation of dermal reactions at the application sites assessed clinically using a visual scale that rates the degree of erythema, edema, and other signs of cutaneous irritation.
Time frame: 6 weeks
To assess safety
Evaluation of any adverse events (AEs) reported during the study.application to the healthy skin of humans.
Time frame: 6 weeks
Ran from Oct 2017 to primary completion in Feb 2018, 4 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Terbinafine
Moberg Pharma AB